Navigation Links
Vasogen Announces First Quarter 2009 Results
Date:4/13/2009

assets. The process has also included a review of the potential out-licensing of assets, lapsing of patents and patent applications, asset divestiture, or liquidation of the Company. At this time, we have significantly narrowed down the number of third party proposals under consideration. If a definitive agreement that the Board believes is in the best interest of our shareholders cannot be reached in the near future, the Board will consider the other alternatives that it has also been evaluating. These alternatives include the potential to realize value from the monetization of certain intangible assets either alone or potentially in combination with a strategic transaction. The Board will continue to assess the merits of these options relative to liquidating the Company and distributing the remaining cash to the shareholders. - As at February 28, 2009, we had cash and cash equivalents of $7.3 million and had 22.5 million common shares issued and outstanding. Other than our accounts payable and accrued liabilities, we do not have any debt. - We sold a United States patent application and its related foreign counterparts for US$0.4 million. This device-based intellectual property has not been used to date in the Celacade System; however, we have retained rights to this technology for any potential use as it relates to our Celacade System. - Subsequent to quarter end, on March 25, 2009, the NASDAQ Stock Market further suspended the enforcement of the Minimum Bid Price Rule requiring a minimum US$1.00 closing price until July 20, 2009. Accordingly, the NASDAQ indicated that it will not take action to delist any security, including our common shares, for a violation of the minimum bid price rule during the suspension. '/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vasogen Announces 2008 Year-End Results
2. Vasogen Announces Sale of Patent Application and Provides Corporate Update
3. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
4. Vasogen Provides Corporate Update
5. Vasogen Announces Third Quarter 2008 Results
6. Vasogen Announces Second Quarter 2008 Results
7. Vasogen Provides Corporate Update
8. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
10. Vasogen Announces Implementation of Strategic Restructuring Plan
11. Vasogen Announces First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... og SHENZHEN , Kina, ... Co., LTD, (BGI Tech), et datterselskab af BGI, ... en ny human whole exome-sekvenseringstjeneste baseret på Complete ... højt anset i branchen for at levere patenterede ... af alle typer varianter, blev købt af BGI ...
(Date:7/22/2014)... 22, 2014 In chemical and ... increasingly common sight. The rapid rise of TDL ... well- established as a core gas measurement technology, ... made them the gas analyzer technology of choice ... encountered in some processes have limited their application ...
(Date:7/22/2014)... 22, 2014 Holomic is expanding ... debut of its fluorescent immunoassay reader, the HRDR-300, ... meeting in Chicago, July 28-31, 2014. Available in ... the HRDR-300 is a highly sensitive, low-cost fluorescent ... fluorescent lateral flow immunoassays with high sensitivity and ...
(Date:7/21/2014)... Livermore, California (PRWEB) July 21, 2014 ... Alameda County Workforce Investment Board (WIB) and Las ... program to provide technical education and hands-on training ... Engineering Technology Program at Las Positas ... and training needed for engineering technician careers, and ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3
... Activity and ... -, - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular ... Targets and Cancer Therapeutics -, GENEVA and ... presentation of new data from an,ongoing Phase 1-2 clinical trial demonstrating that the ...
... 20th EORTC-NCI-AACR Symposium -, SOUTH SAN ... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), ... positive incremental data from,its ongoing Phase 2 ... and prednisone as first-line therapy for metastatic,hormone-refractory ...
... Group Corporation,("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical ... owned Japanese subsidiary, has,entered into a binding letter ... First Section Index: 4514) for the commercialization of,the ... an oral emergency contraceptive "morning after pill",which is ...
Cached Biology Technology:Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 2Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 3Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 4Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 5Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R)) 2
(Date:7/22/2014)... of planthopper known as Conosimus, which now includes six ... the southern part of the Iberian Peninsula in the ... in the open-access Journal of Insect Science ... Conosimus baenai , has been named after Manuel Baena, ... of Iberian Hemiptera. , Conosimus baenai differs ...
(Date:7/21/2014)... Millar , a professor of entomology and ... at the University of California, Riverside, has been ... International Society of Chemical Ecology ( ISCE ). , ... is the society,s highest honor. It is awarded ... chemical ecology, the study of chemicals that mediate interactions ...
(Date:7/21/2014)... monitor seals, every movement, researchers have shown for the ... offshore wind farms and pipelines. Those man-made structures probably ... to a study published in the Cell Press journal ... "I was shocked when I first saw the stunning ... an offshore wind farm in the United Kingdom, says ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2Seals forage at offshore wind farms 2
... 2008 The first study to determine the global ... sharks and rays reveals serious overfishing and recommends key ... findings and recommendations for action are published in the ... This international study, organised by the IUCN Shark ...
... are only four specimens of the Yangtze giant softshell ... in captivity. In order to save this species from ... and the Turtle Survival Alliance (TSA), working in conjunction ... Zoo Society, recently paired two of them. A ...
... around $120, U.S. drivers can expect to pay more at ... study by Rice University,s Baker Institute for Public Policy. ... up," said Kenneth Medlock III, a Baker Institute fellow in ... cautioned that seasonal variability and other factors could affect prices ...
Cached Biology News:Over 50 percent of oceanic shark species threatened with extinction 2Relocation of endangered Chinese turtle may save species 2Baker Institute study finds continuing upward pressure on retail gasoline prices 2
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Biology Products: